Frontline Bruton tyrosine kinase inhibitors are associated with improved response and PFS in primary CNS lymphoma.

Authors

Xiaoxiao Wang, Bing Bai, Shanshan Yu, Lei Wen, Xingyuan Shi, Huiqiang Huang

Published in

Blood advances. Oct 23, 2026. Epub Oct 23, 2026.

Abstract

High-dose methotrexate (HD-MTX)-based immunochemotherapy remains the standard for primary CNS lymphoma (PCNSL), yet relapse rates are high and outcomes suboptimal. While Bruton's tyrosine kinase inhibitors (BTKi) demonstrate efficacy in trials, their comparative benefit against conventional regimens in heterogeneous real-world populations remains undefined. We conducted a retrospective study of 131 newly diagnosed patients stratified by frontline induction therapy (BTKi-based, n=85; conventional, n=46), utilizing multiple imputation (m=50) and inverse probability of treatment weighting (IPTW) to balance baseline covariates. In the primary pooled multiple-imputation IPTW analysis, BTKi-based therapy was associated with improved PFS (HR 0.57, 95% CI 0.32-1.00; P=0.048) and a higher complete response rate (OR 5.50, 95% CI 2.25-13.47; P<0.001). The objective response rate was also higher (OR 2.59, 95% CI 1.05-6.36; P=0.038). The overall survival difference was not statistically significant (HR 0.65, 95% CI 0.31-1.38; P=0.263), which may reflect multifactorial confounding inherent in this retrospective comparison. These findings suggest that integrating BTKi into frontline regimens is associated with a favorable PFS profile and improved response in newly diagnosed PCNSL, while definitive OS conclusions cannot be drawn.

PMID:
42913449
Bibliographic data and abstract were imported from PubMed on 24 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.